Astrazeneca (AZN) Non-Current Debt (2009 - 2026)
Astrazeneca (AZN) posted quarterly Non-Current Debt of $23.7 billion for Q2 2026, down 4.17% year-over-year from $24.7 billion in Q2 2025, and up 191.29% quarter-over-quarter from -$25.9 billion in Q1 2026.
Astrazeneca (AZN) Non-Current Debt (2009 - 2026) Analysis & Trends
Astrazeneca's Non-Current Debt history runs 18 years deep, the most recent figure standing at $23.7 billion for Q2 2026.
- In Q2 2026, Non-Current Debt fell 4.17% year-over-year to $23.7 billion; the TTM figure through Jun 2026 stood at $23.7 billion (down 4.17% YoY), while the FY2025 annual figure was $24.7 billion, down 6.76% from the prior year.
- Non-Current Debt for Q2 2026 stood at $23.7 billion, up from -$25.9 billion in the prior quarter.
- The five-year high for Non-Current Debt was $27.2 billion in Q2 2024, with the low at -$26.4 billion in Q1 2024.
- The 5-year median for Non-Current Debt is -$503.0 million (2023), against an average of -$222.3 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt tumbled 161.5% in 2022, then gained 18.52% in 2024.
- Astrazeneca's Non-Current Debt stood at $23.0 billion in 2022, then declined by 2.61% to $22.4 billion in 2023, then climbed by 18.52% to $26.5 billion in 2024, then retreated by 6.76% to $24.7 billion in 2025, then declined by 4.18% to $23.7 billion in 2026.
- Business Quant data shows AZN's Non-Current Debt at $23.7 billion in Q2 2026, -$25.9 billion in Q1 2026, and $24.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 54.97 Bn | 47.59 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.68 Bn |
| Mar 31, 2026 | -25.94 Bn |
| Dec 31, 2025 | 24.72 Bn |
| Sep 30, 2025 | -23.97 Bn |
| Jun 30, 2025 | 24.71 Bn |
| Mar 31, 2025 | -26.07 Bn |
| Dec 31, 2024 | 26.51 Bn |
| Sep 30, 2024 | -26.35 Bn |
| Jun 30, 2024 | 27.23 Bn |
| Mar 31, 2024 | -26.45 Bn |
| Dec 31, 2023 | 22.37 Bn |
| Sep 30, 2023 | -23.37 Bn |
| Jun 30, 2023 | 24.33 Bn |
| Mar 31, 2023 | -25.06 Bn |
| Dec 31, 2022 | 22.97 Bn |
| Sep 30, 2022 | -24.54 Bn |
| Jun 30, 2022 | 26.46 Bn |
| Mar 31, 2022 | -25.22 Bn |
| Dec 31, 2021 | 28.13 Bn |
| Sep 30, 2021 | -24.67 Bn |